The 1Q 2019 revenue is significant and suggests SNN will make or exceed 2019 revenue guidance (impressive compared to higher cap competitors).
Am I correct that for this revenue SNN currently does not grow their own but instead buys from 3rd parties? Replacing 3rd party purchases with their own product might improve margins but will not increase revenue.
I like the plan/capacity to extract and market oils. Economies of scale in a higher margin product is a winner.
I never thought it made sense to grow in the Canadian high cost indoor producer environment. With adult /recreational market developing I think medicinal market days are numbered (so the high cost doc/clinic patient driver will be a loser).
I get the shelf space challenge but I don’t believe in the value of grow to table vertical intervention"
"They planned these quarter report prefect. Q1 is at the end of next month. They new pulling out of Canada would have a sell off. With them coming out with Q1 2019 in 30 days tells me they will crush earnings. I’m buying every share I can."
News 
Market Data 
Discover 
